Amine A. Kamen

Latest

• Critical Assessment of Purification and Analytical Technologies for Enveloped Viral Vector and Vaccine Processing and Their Current Limitations in Resolving Co-Expressed Extracellular Vesicles
• Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation
• Recent advances and current challenges in process intensification of cell culture-based influenza virus vaccine manufacturing
• Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures
• Bioreactor production of rVSV-based vectors in Vero cell suspension cultures
• Cross-Validation of ELISA and a Portable Surface Plasmon Resonance Instrument for IgG Antibodies Serology with SARS-CoV-2 Positive Individuals
• Advancements in molecular design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-cell baculovirus expression platform
• Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation
• Vero cell upstream bioprocess development for the production of viral vectors and vaccines
• A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms
• Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa
• Titration methods for rVSV-based vaccine manufacturing
• Serum-free production of rVSV-ZEBOV in Vero cells: microcarrier bioreactor versus scale-X™ hydro fixed-bed
• Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells
• Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells